Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $255.25M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.26M
Average 0.74M
QTTB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Q32 Bio Inc.NASDAQ: QTTB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.55M rose 15.4% year over year, ahead of the -24.8% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +61.9% a year.
Context
- Stock-based compensation amounted to 9.8% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +15.4% holds above the trailing-twelve-month pace of -24.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.26M USD
- Year-over-year change
- +19.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.26M | +19.8% |
| FY2024 | 2024-12-31 | 4.39M | +207.1% |
| FY2023 | 2023-12-31 | 1.43M | +15.3% |
| FY2022 | 2022-12-31 | 1.24M | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How QTTB compares with its peers on the latest reported figures
- QTTB's LTM Mar 2026 stock-based compensation of $3.99M is the 4th largest of the 5 companies compared; the peer median is $4.99M.
- Its year-over-year change of -24.8% is the 2nd highest of 5, against a peer median of -37.5%.
- Stock-based compensation amounts to 7.4% of revenue for QTTB, versus a peer median of 8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $21.34M | +832.2% | +24.9% | — | |
| LTM Mar 2026 | $5.66M | -29.3% | +12.5% | — | |
| LTM Mar 2026 | $4.33M | -45.8% | +38.8% | — | |
| LTM Mar 2026 | $3.99M | -24.8% | +61.9% | 7.4% | |
| LTM Mar 2026 | $3.19M | -47.9% | -12.7% | 8.6% | |
| Peer median (excluding QTTB) | $4.99M | -37.5% | +18.7% | 8.6% | |
Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (95.76M) | (42.81M) | (53.74M) | (47.73M) | 29.82M |
| Depreciation & Amortization | 9.54M | 370K | 499K | 487K | 391K |
| Deferred Income Tax | 0 | 2.43M | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 1.24M | 1.43M | 4.39M | 5.26M |
| Change in Working Capital | (41.8M) | 26.94M | 26.32M | (9.64M) | (4.04M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.49M) | (1.24M) | 2.03M | (1.04M) | (2.11M) |
| Other Working Capital | (39.32M) | 28.18M | 24.28M | (8.59M) | (1.93M) |
| Other Non-Cash Items | 18.27M | 876K | 6.82M | (15.22M) | (64.97M) |
| Operating Cash Flow | (109.75M) | (10.96M) | (18.68M) | (67.72M) | (33.54M) |
| Capital Expenditures | (2.4M) | (2.49M) | (5K) | (75K) | 0 |
| Acquisitions (Net) | 0 | 130M | 0 | 0 | 0 |
| Purchases of Investments | (97.39M) | (157.46M) | 0 | 0 | 0 |
| Sales of Investments | 49M | 65.46M | 0 | 20M | 0 |
| Other Investing Activities | 0 | (37.98M) | 0 | 0 | 7M |
| Investing Cash Flow | (50.79M) | (2.47M) | (5K) | 19.93M | 7M |
| Debt Repayment | 0 | 30M | 300K | 7M | (3.13M) |
| Common Stock Issued | 52.17M | 69K | 106K | 42M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 46.14M | 0 |
| Financing Cash Flow | 52.17M | 30.07M | 406K | 95.14M | (3.13M) |
| Effect of Forex Changes | (679K) | 0 | 9.91M | 0 | 0 |
| Net Change in Cash | (109.05M) | 16.65M | (8.37M) | 47.35M | (29.67M) |
| Free Cash Flow | (112.15M) | (13.44M) | (18.68M) | (67.79M) | (33.54M) |
Q32 Bio Inc.
NASDAQ:QTTB
Intrinsic Alpha fair value
Locked
Current Price
$8.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.